NASDAQ:LUMO Lumos Pharma (LUMO) Stock Forecast, Price & News $3.88 +0.29 (+8.08%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$3.60▼$3.9250-Day Range$3.01▼$3.9652-Week Range$2.95▼$9.56Volume20,008 shsAverage Volume16,755 shsMarket Capitalization$31.70 millionP/E RatioN/ADividend YieldN/APrice Target$17.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Lumos Pharma MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside355.3% Upside$17.67 Price TargetShort InterestBearish3.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.28Based on 2 Articles This WeekInsider TradingSelling Shares$7,240 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.88) to ($2.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector406th out of 983 stocksPharmaceutical Preparations Industry193rd out of 486 stocks 3.4 Analyst's Opinion Consensus RatingLumos Pharma has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.67, Lumos Pharma has a forecasted upside of 355.3% from its current price of $3.88.Amount of Analyst CoverageLumos Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted3.73% of the float of Lumos Pharma has been sold short.Short Interest Ratio / Days to CoverLumos Pharma has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in Lumos Pharma has recently increased by 1.26%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLumos Pharma does not currently pay a dividend.Dividend GrowthLumos Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LUMO. Previous Next 2.4 News and Social Media Coverage News SentimentLumos Pharma has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lumos Pharma this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Lumos Pharma to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lumos Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,240.00 in company stock.Percentage Held by Insiders23.70% of the stock of Lumos Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.53% of the stock of Lumos Pharma is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lumos Pharma are expected to grow in the coming year, from ($3.88) to ($2.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lumos Pharma is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lumos Pharma is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLumos Pharma has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lumos Pharma (NASDAQ:LUMO) StockLumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.Read More Receive LUMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LUMO Stock News HeadlinesMay 31, 2023 | finance.yahoo.comLumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare ConferenceMay 28, 2023 | finance.yahoo.comDaniel Farb Buys 22% More Lumos Pharma SharesJune 2, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 26, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Hold Rating on Spectrum Pharmaceuticals (SPPI)May 25, 2023 | finance.yahoo.comLumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21stMay 22, 2023 | finance.yahoo.comLumos Pharma to Participate in World Orphan Drug Congress USAMay 16, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)May 15, 2023 | americanbankingnews.comFinancial Comparison: Lumos Pharma (NASDAQ:LUMO) and IDEAYA Biosciences (NASDAQ:IDYA)June 2, 2023 | Behind the Markets (Ad)"How war impacts the stock market"Russia's invasion of Ukraine has already sent the stock market down 10%. But that's just the opening act for the new Russia-China Alliance. There's a major event involving China that's heating up... and it could boil over as soon as April 16th, 2023. Click Here to Learn How to Protect Your RetirementMay 11, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on TRACON Pharmaceuticals (TCON)May 10, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Lumos Pharma, Inc. (NASDAQ:LUMO) Raised by AnalystMay 8, 2023 | finance.yahoo.comEncouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)May 5, 2023 | msn.comHC Wainwright & Co. Reiterates Lumos Pharma (LUMO) Buy RecommendationMay 4, 2023 | finanznachrichten.deLumos Pharma, Inc.: Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical UpdatesMay 4, 2023 | marketwatch.com8-K: LUMOS PHARMA, INC.May 3, 2023 | msn.comLumos Pharma GAAP EPS of -$0.89 beats by $0.24, revenue of $0.69M beats by $0.57MMay 3, 2023 | msn.comLumos Pharma: Q1 Earnings InsightsMay 3, 2023 | finance.yahoo.comLumos Pharma (LUMO) Reports Q1 Loss, Tops Revenue EstimatesMay 3, 2023 | finance.yahoo.comLumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical UpdatesMay 1, 2023 | americanbankingnews.comLumos Pharma (LUMO) to Release Quarterly Earnings on WednesdayApril 27, 2023 | finance.yahoo.comData from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)April 19, 2023 | finance.yahoo.comLumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023March 24, 2023 | markets.businessinsider.comOppenheimer Remains a Buy on Soleno Therapeutics (SLNO)March 22, 2023 | finance.yahoo.comWe Think Lumos Pharma (NASDAQ:LUMO) Needs To Drive Business Growth CarefullyMarch 9, 2023 | finance.yahoo.comLumos Pharma to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023March 6, 2023 | insidermonkey.comLumos Pharma, Inc. (NASDAQ:LUMO) Q4 2022 Earnings Call TranscriptMarch 5, 2023 | finance.yahoo.comAdditional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric EndocrinologySee More Headlines LUMO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LUMO Company Calendar Last Earnings5/03/2023Today6/02/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LUMO CUSIPN/A CIK1126234 Webwww.lumos-pharma.com Phone(512) 215-2630Fax515-296-3520Employees29Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.67 High Stock Price Forecast$28.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+363.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,060,000.00 Net Margins-1,459.25% Pretax Margin-1,459.87% Return on Equity-48.26% Return on Assets-40.83% Debt Debt-to-Equity RatioN/A Current Ratio12.61 Quick Ratio12.61 Sales & Book Value Annual Sales$1.52 million Price / Sales20.48 Cash FlowN/A Price / Cash FlowN/A Book Value$6.43 per share Price / Book0.59Miscellaneous Outstanding Shares8,170,000Free Float6,234,000Market Cap$31.13 million OptionableNot Optionable Beta0.95 Key ExecutivesRichard J. HawkinsChairman & Chief Executive OfficerJohn C. McKewPresident & Chief Scientific OfficerRobert J. DavisVice President-Clinical OperationsLori LawleyChief Financial OfficerDavid B. KarpfChief Medical OfficerKey CompetitorsYumanity TherapeuticsNASDAQ:YMTXMinerva NeurosciencesNASDAQ:NERVPurple BiotechNASDAQ:PPBTFlora GrowthNASDAQ:FLGCBullfrog AINASDAQ:BFRGView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCSold 3,200 shares on 5/12/2023Ownership: 2.814%Private Advisor Group LLCBought 20,013 shares on 5/10/2023Ownership: 0.245%Marquette Asset Management LLCBought 10,068 shares on 5/1/2023Ownership: 0.379%Greenwich Wealth Management LLCBought 30,028 shares on 4/24/2023Ownership: 0.366%John C MckewSold 2,214 sharesTotal: $7,239.78 ($3.27/share)View All Insider TransactionsView All Institutional Transactions LUMO Stock - Frequently Asked Questions Should I buy or sell Lumos Pharma stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lumos Pharma in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LUMO shares. View LUMO analyst ratings or view top-rated stocks. What is Lumos Pharma's stock price forecast for 2023? 5 brokerages have issued 1 year price objectives for Lumos Pharma's stock. Their LUMO share price forecasts range from $7.00 to $28.00. On average, they expect the company's share price to reach $17.67 in the next twelve months. This suggests a possible upside of 363.7% from the stock's current price. View analysts price targets for LUMO or view top-rated stocks among Wall Street analysts. How have LUMO shares performed in 2023? Lumos Pharma's stock was trading at $3.61 at the start of the year. Since then, LUMO stock has increased by 5.5% and is now trading at $3.81. View the best growth stocks for 2023 here. When is Lumos Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our LUMO earnings forecast. How were Lumos Pharma's earnings last quarter? Lumos Pharma, Inc. (NASDAQ:LUMO) posted its earnings results on Wednesday, May, 3rd. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.23. The firm had revenue of $0.69 million for the quarter, compared to analysts' expectations of $0.31 million. Lumos Pharma had a negative trailing twelve-month return on equity of 48.26% and a negative net margin of 1,459.25%. What other stocks do shareholders of Lumos Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lumos Pharma investors own include Advanced Micro Devices (AMD), Agilent Technologies (A), Air Lease (AL), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), Chimerix (CMRX), Compagnie de Saint-Gobain (CODYY) and What is Lumos Pharma's stock symbol? Lumos Pharma trades on the NASDAQ under the ticker symbol "LUMO." Who are Lumos Pharma's major shareholders? Lumos Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.81%), Marquette Asset Management LLC (0.38%), Greenwich Wealth Management LLC (0.37%) and Private Advisor Group LLC (0.24%). Insiders that own company stock include James E Flynn, John C Mckew, Kevin M Lalande, Kevin M Lalande, Richard J Hawkins and Thomas A Raffin. View institutional ownership trends. How do I buy shares of Lumos Pharma? Shares of LUMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lumos Pharma's stock price today? One share of LUMO stock can currently be purchased for approximately $3.81. How much money does Lumos Pharma make? Lumos Pharma (NASDAQ:LUMO) has a market capitalization of $31.13 million and generates $1.52 million in revenue each year. The company earns $-31,060,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. How can I contact Lumos Pharma? Lumos Pharma's mailing address is 4200 MARATHON BLVD. SUITE 200, AUSTIN TX, 78756. The official website for the company is www.lumos-pharma.com. The company can be reached via phone at (512) 215-2630, via email at investor@linkp.com, or via fax at 515-296-3520. This page (NASDAQ:LUMO) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lumos Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.